Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17277958 | 0.91 | MEN1 (0.31) | ELANEMEN1KMT2A | |
| SCHEMBL17280435 | 0.89 | ELANE (0.30) | ELANEL3MBTL1 | |
| SCHEMBL17277991 | 0.85 | APEX1 (0.33) | — | |
| SCHEMBL17277957 | 0.84 | ELANE (0.35) | ELANENPSR1MEN1KMT2A | |
| SCHEMBL17277961 | 0.83 | ELANE (0.31) | ELANECYP2C9CYP2C19NPSR1SMN1; SMN2 | |
| SCHEMBL17364572 | 0.83 | ALDH1A1 (0.30) | — | |
| SCHEMBL17277973 | 0.82 | — | — | |
| SCHEMBL14462077 | 0.82 | L3MBTL1 (0.36) | L3MBTL1TDP1HPGDTSHRMAPK1 | |
| SCHEMBL17280436 | 0.82 | MEN1 (0.32) | ELANEMEN1KMT2A | |
| SCHEMBL17277995 | 0.81 | L3MBTL1 (0.36) | ELANEL3MBTL1TDP1CISD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947090-B1 | NOVEL MONOPHOSPHITE LIGANDS WITH A TERTIARY BUTYLOXYCARBONYL GROUP | EVONIK DEGUSSA GMBH (DE) | 2016-08-24 | — | — | EP | disclosed |
| US-9221850-B2 | Monophosphite ligands having a tert-butyloxycarbonyl group | EVONIK INDUSTRIES AG (DE) | 2015-12-29 | — | — | US | disclosed |
| US-9221850-B2 | Monophosphite ligands having a tert-butyloxycarbonyl group | EVONIK INDUSTRIES AG (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20150336988-A1 | NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP | EVONIK INDUSTRIES AG (DE) | 2015-11-26 | — | — | US | disclosed |
| US-20150336988-A1 | NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP | EVONIK INDUSTRIES AG (DE) | 2015-11-26 | — | — | US | disclosed |
| EP-2947090-A1 | NOVEL MONOPHOSPHITE LIGANDS WITH A TERTIARY BUTYLOXYCARBONYL GROUP | Evonik Industries AG (DE) | 2015-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336988-A1 | NOVEL MONOPHOSPHITE LIGANDS HAVING A TERT-BUTYLOXYCARBONYL GROUP | TERF2, NUDT1, TERF2IP | ELANE 2196/4885L3MBTL1 681/4885TDP1 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.